Clinical trial
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
NCT00106626 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00106626 |
|---|---|
| Title | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors |
| Official title | Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin |
| Enrollment | 52 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 29, 2005 |
| Last update posted | Apr 22, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: